AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, held May 31-June 4, at McCormick Place Convention Center in Chicago, IL.

“We look forward to presenting our preliminary data at ASCO, and to provide initial safety and efficacy results from our Phase 1 trial evaluating AIC100 CAR T therapy in patients with advanced thyroid cancers,” said Matt Britz, CEO, AffyImmune. “These results mark significant progress, as we continue to advance our affinity-tuned CAR T therapies for patients with unmet medical need.”

Presentation Details:

Title: Safety and Efficacy of AIC100 Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients with Advanced Thyroid Cancers: results from the phase 1 study

Presenter: Dr. Samer Ali Srour, University of Texas MD Anderson Cancer Center

Session Type: Poster Session– Head and Neck Cancer

Abstract Number: 6112

Date and Time: June 2, 2024: 9:00 AM - 12:00 PM CDT

Location: McCormick Place Convention Center in Chicago, Illinois

About AffyImmune Therapeutics

AffyImmune is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies to transform the lives of patients with cancer. The Company’s proprietary technology utilizing ICAM-1/LFA-1 interaction can potentially address all critical CAR T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion, while also allowing in vivo tracking of the CAR T cells. Its lead candidate, AIC100, is an ICAM-1-directed CAR T therapy being developed for patients with advanced thyroid cancer. AffyImmune is developing a focused pipeline of therapeutics targeting ICAM-1 in oncologic indications with high unmet medical need. AffyImmune is based in Natick, MA. For more information, visit www.affyimmune.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424393341/en/